Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study.
- DOI
- 10.1016/j.eclinm.2023.102394
- Published
- 2024 Jan
- Container
- EClinicalMedicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.eclinm.2023.102394,
title = {Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study.},
author = {Khanani AM and Boyer DS and Wykoff CC and Regillo CD and Busbee BG and Pieramici D and Danzig CJ and Joondeph BC and Major JC Jr and Turpcu A and Kiss S},
year = {2024},
journal = {EClinicalMedicine},
doi = {10.1016/j.eclinm.2023.102394},
url = {https://doi.org/10.1016/j.eclinm.2023.102394}
}RIS
TY - JOUR TI - Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. AU - Khanani AM AU - Boyer DS AU - Wykoff CC AU - Regillo CD AU - Busbee BG AU - Pieramici D AU - Danzig CJ AU - Joondeph BC AU - Major JC Jr AU - Turpcu A AU - Kiss S PY - 2024 JO - EClinicalMedicine DO - 10.1016/j.eclinm.2023.102394 UR - https://doi.org/10.1016/j.eclinm.2023.102394 ER -
APA
AM, K., DS, B., CC, W., CD, R., BG, B., D, P., CJ, D., BC, J., Jr, M. J., A, T., & S, K. (2024). Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2023.102394
Source records
- pubmed · retrieved 2026-09-26T20:50:23.117Z